United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
528.47
-1.06 (-0.20%)
Jul 24, 2026, 4:00 PM EDT - Market closed
United Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,280 | 1,557 | 1,697 | 1,208 | 961.2 | 894.8 |
Short-Term Investments | 874 | 1,363 | 1,570 | 1,786 | 1,878 | 1,036 |
Cash & Short-Term Investments | 2,154 | 2,920 | 3,267 | 2,994 | 2,839 | 1,931 |
Cash Growth | -35.15% | -10.61% | 9.12% | 5.47% | 47.03% | 5.21% |
Accounts Receivable | 312 | 350.2 | 279.3 | 278.9 | 220.4 | 198.7 |
Inventory | 178.3 | 183.1 | 157.9 | 111.8 | 102 | 93.8 |
Other Current Assets | 228 | 248.9 | 169.7 | 166.2 | 219.2 | 100.4 |
Total Current Assets | 2,872 | 3,703 | 3,874 | 3,551 | 3,380 | 2,324 |
Net Property, Plant & Equipment | 1,841 | 1,730 | 1,222 | 1,045 | 861.5 | 780.9 |
Goodwill | 115.5 | 116.5 | 111.9 | 114.2 | 44.5 | 44.6 |
Long-Term Investments | 1,317 | 1,777 | 1,475 | 1,910 | 1,316 | 1,650 |
Other Long-Term Assets | 568.6 | 554.6 | 680.5 | 546.6 | 442 | 370.1 |
Total Assets | 6,714 | 7,880 | 7,364 | 7,167 | 6,045 | 5,169 |
Accounts Payable | 498.3 | 488 | 344.5 | 298 | 229.9 | 174.6 |
Short-Term Debt | - | - | 300 | 400 | - | - |
Other Current Liabilities | 100.8 | 72.6 | 93.6 | 106.4 | 113.3 | 130.8 |
Total Current Liabilities | 599.1 | 560.6 | 738.1 | 804.4 | 343.2 | 305.4 |
Long-Term Debt | - | - | - | 300 | 800 | 800 |
Other Long-Term Liabilities | 214 | 223.2 | 181.9 | 77.8 | 104.6 | 104.8 |
Total Long-Term Liabilities | 214 | 223.2 | 181.9 | 377.8 | 904.6 | 904.8 |
Total Liabilities | 813.1 | 783.8 | 920 | 1,182 | 1,248 | 1,210 |
Common Stock | 0.8 | 0.8 | 0.8 | 0.7 | 0.7 | 0.7 |
Treasury Stock | -5,442 | -4,260 | -3,475 | -2,579 | -2,579 | -2,579 |
Additional Paid-in Capital | 2,520 | 2,798 | 2,699 | 2,549 | 2,388 | 2,245 |
Accumulated Other Comprehensive Income | -10.2 | 0.9 | -3.4 | -12.8 | -55.5 | -23 |
Retained Earnings | 8,832 | 8,557 | 7,222 | 6,027 | 5,042 | 4,315 |
Shareholders' Equity | 5,901 | 7,096 | 6,444 | 5,985 | 4,797 | 3,959 |
Total Liabilities & Equity | 6,714 | 7,880 | 7,364 | 7,167 | 6,045 | 5,169 |
Total Debt | - | 0 | 300 | 700 | 800 | 800 |
Net Cash (Debt) | 2,154 | 2,920 | 2,967 | 2,294 | 2,039 | 1,131 |
Net Cash Growth | -31.00% | -1.57% | 29.33% | 12.53% | 80.30% | 9.25% |
Net Cash Per Share | 45.32 | 60.97 | 61.17 | 46.16 | 42.03 | 23.91 |
Book Value | 5,901 | 7,096 | 6,444 | 5,985 | 4,797 | 3,959 |
Book Value Per Share | 124.17 | 148.15 | 132.87 | 120.42 | 98.90 | 83.70 |
Tangible Book Value | 5,786 | 6,980 | 6,332 | 5,871 | 4,752 | 3,914 |
Tangible Book Value Per Share | 121.74 | 145.71 | 130.56 | 118.12 | 97.98 | 82.75 |